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Abstract
Background: Glycosylated proteins and lipids are important regulatory factors whose functions
can be altered by addition or removal of sugars to the glycan structure. The glycans are recognized
by sugar-binding lectins that serve as receptors on the surface of many cells and facilitate initiation
of an intracellular signal that changes the properties of the cells. We identified a peptide that mimics
the ligand of an N-acetylgalactosamine (GalNAc)-specific lectin and asked whether the peptide
would express specific biological activity.
Findings: A 12-mer phage display library was screened with a GalNAc-specific lectin to identify an
amino acid sequence that binds to the lectin. Phage particles that were eluted from the lectin with
free GalNAc were considered to have been bound to a GalNAc-binding site. Peptides were
synthesized with the selected sequence as a quadravalent structure to facilitate receptor
crosslinking. Treatment of human peripheral blood mononuclear cells for 24 h with the peptide
stimulated secretion of interleukin-8 (IL-8) but not of IL-1β, IL-6, IL-10, or tumor necrosis factor-
α (TNF-α). The secretion of IL-21 was stimulated as strongly with the peptide as with interferon-γ.
Conclusion: The data indicate that the quadravalent peptide has biological activity with a degree
of specificity. These effects occurred at concentrations in the nanomolar range, in contrast to free
sugars that generally bind to proteins in the micro- to millimolar range.
Background
Many cells express cell-surface receptors that bind sugar-
containing ligands and serve important regulatory func-
tions [1]. Extensive research over the past two decades has
been devoted to design of peptide mimetics of sugars [2]
to serve as vaccines that elicit anti-carbohydrate antibod-
ies [3,4] or to bind with high affinity to specific antibodies
[5,6]. We asked whether a peptide mimetic of N-acetylga-
lactosamine (GalNAc) could be identified that induces
specific responses. For this purpose, a phage display
library was screened with a GalNAc-specific lectin as a
receptor analog. A consensus amino acid sequence
emerged in the variable region of the pIII protein in the
selected phage particles. Because clusters of GalNAc bind
to receptors with higher affinity than a single residue [7],
and receptor crosslinking is often required for many signal
transduction mechanisms [8], we designed and tested a
multivalent structure containing this sequence.
Selection and synthesis of a GalNAc mimetic
The lectin from Helix pomatia (HPA) binds O-linked α-
GalNAc but also recognizes Gal (β1–3) GalNAc and α-
GlcNAc [9,10]. KA values for interactions of HPA with
groups containing terminal GalNAc range from 0.1 mM to
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lectins [11]. HPA binds to the single O-linked α-GalNAc
on the serum macrophage activating factor (GcMAF) [12].
A M13 bacteriophage library consisting of randomized
12-mer sequences at the N-terminus of the pIII protein
was screened for an amino acid sequence that would bind
to this lectin. Bound phage particles were eluted from the
lectin with free GalNAc to ensure specificity of selection.
Table 1 lists amino acid sequences of the variable region
of phage particles enriched by four cycles of selection,
from which a consensus sequence, VQATQSNQHTPR,
emerged. [An extensive screen of linear and disulfide-con-
strained 7-mer phage libraries failed to provide a consen-
sus sequence (data not shown)].
The peptide was added to a tri-Lys core [13], which pro-
vided four identical sequences within the same structure
(designated L4). A GGGS sequence, adjacent to the varia-
ble region in the pIII protein, was retained as a spacer to
move the mimetic sequence away from the core. A dansyl
group was attached to the sulfhydryl group of C-terminal
Cys to provide a chromophore for determination of con-
centration and detection by fluorescence. The structure of
the final product was [(VQATQSNQHTPRGGGS)2K]2K-βA-(S-dansyl)C (Fig. 1). The peptide was also synthesized
with the C-terminal βA-(S-dansyl)C replaced with ε-bioti-
nyl-K. All peptides terminated with an amide group at the
C-terminus.
The mass spectrum of dansylated L4 contained a signal for
the singly-charged (m+1) molecule of 7,310 Da, which
was identical to the calculated mass of the protonated
quadravalent structure (Fig. 1). The signal at m/z = 3,656
Da corresponded to the doubly-charged peptide.
Lectin binding
Whether L4 expressed characteristics of a sugar was tested
by two methods. Lectins whose primary specificities are
GalNAc (Helix pomatia, HPA); GlcNAc or NeuNAc (wheat
germ agglutinin, WGA); Gal [Griffonia (Bandeiraea) sim-
plicifolia isolectin B4, BS]; and Man or Glc (concanavalin
A, ConA), were fixed onto a glass slide. Non-specific sites
were blocked with gelatin, and the slide was then incu-
bated with biotin-tagged L4. Binding was detected by add-
ing streptavidin labeled with the fluorescent dye Cy3.
Lectins were spotted in triplicate to minimize conclusions
from inaccurate delivery, as indicated by the top row of
ConA. All four lectins bound L4, with strongest binding
found with the Gal-specific lectin, BS (Fig. 2A). Binding
was also observed with HPA and with WGA, which binds
to clusters of GalNAc [14,15].
In a second assay, biotin-tagged L4 was first bound in
wells of a microtiter plate coated with streptavidin, and
the extent of binding was measured by activity of horse-
radish peroxidase conjugated to lectins that were retained
in the wells. The Gal-specific lectin BS again bound most
extensively to L4 (Fig. 2B). Binding of the lectins to a con-
trol peptide, synthesized with the spacer sequence
repeated (i.e., VGGGSGGGS-), was not detected (Fig. 2B).
These binding assays were designed to maintain maximal
flexibility of the peptide. When adsorbed onto clean pol-
ystyrene surfaces of wells of a microtiter plate, as done in
conventional solid-phase binding assays [13,16], the arms
of the peptide are most likely immobilized. In such assays,
binding of BS was negligible while binding to WGA and
ConA increased (data not shown).
Biological activity of the mimetic peptide
Cytotoxicity
L4, from 3 nM to 90 μM, did not affect the proliferation of
human peripheral blood mononuclear cells (PBMCs)
when measured by the incorporation of bromo-deoxyuri-
dine into DNA over a 48-h period (data not shown).
Cytokine release
Cytokines, which include interleukins (IL's) and chemok-
ines, are regulatory proteins that are released from acti-
vated cells and act as intercellular mediators in the
generation of a response. A preliminary survey to deter-
mine whether L4 induces a change in secretion of
cytokines from human PBMCs indicated that IL-15,
Eotaxin and TIMP-2 increased approximately two-fold
over control levels in the culture medium in response to a
4-h treatment with 100 nM L4. In contrast, the amounts
of IL-2 and IL-8 in the medium were approximately half
of that in the control culture that received phosphate-buff-
ered saline (PBS), the vehicle, in place of the peptide solu-
tion. No significant changes were detected from control
samples in the amounts of other cytokines, including IL-
Table 1: Amino acid sequences of the N-terminus of protein PIII 
from separate phage plaques after 4 cycles of selection.
A Q A L G L S A I S P R
V Q A T Q S N Q H T P R
E Q A T P R N H N S P P
V Q A T P R L Q H T P R
A Q G P P S K Q H S P P
V Q A I Q S N Q L T P R
V Q A T T V Q I Q H A P
V Q A G Q S N A H T A G
V Q A T Q S N Q H T P R
V Q A R Q S N Q H T P R
V Q N Y Q S N Q H T P R
T F A T Q S N Q H T P R
Consensus
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IL-8, G-CSF, I-309 and Eotaxin-2 were significantly ele-
vated in the medium (data not shown).
To quantitatively assess effects of L4 on cells, secretion of
several key cytokines by PBMCs was assayed after incuba-
tion for 24 h with L4 or with lipopolysaccharide (LPS), the
prototypic inflammatory agent, as a positive control. LPS
(1 ng/ml) strongly stimulated secretion of cytokines IL-
1β, IL-6, IL-8, IL-10 and TNF-α. The peptide at relatively
high concentrations (e.g., 30 μM and 90 μM, Fig. 3A, B, D)
weakly but significantly inhibited release of IL-1β, IL-6
and TNF-α induced by LPS. The amounts of these
cytokines in media of cultures treated with peptide alone
were not significantly different from controls (Fig. 3A to
3D). In contrast, secretion of IL-8 was stimulated by the
peptide nearly as strongly as with LPS, with maximal
secretion at 3 and 300 nM L4 (Fig. 3E). Higher concentra-
tions, e.g., 3 to 30 μM, inhibited release of IL-8 as com-
pared with the untreated, control level (light green bar).
IL-8 is a chemokine released from activated macrophages
that attracts neutrophils and plays an important role in
host defense by enhancing microbicidal activity and cyto-
toxicity [17,18]. For example, IL-8 dramatically reduced
growth of human ovarian cancer cells and mediated
effects of the chemotherapeutic drug paclitaxel by target-
ing neutrophils and monocytes to the tumor [18].
IL-21, a cytokine secreted from activated T cells, is of par-
ticular interest in regard to its pleiotropic immunomodu-
latory and anti-tumor activities [19,20]. A 16-h treatment
of PBMCs with 50 nM L4 induced as strong a release of IL-
21 as a highly effective concentration [1 nM (400 U/ml)]
of IFN-γ, a known stimulant of IL-21 release [19] (Fig. 4).
The low control value indicated that the peptide expressed
an activity not provided by proteins and other factors
from serum in the culture medium. IL-21 is most homol-
ogous to IL-15 and to a lesser extent IL-2. IL-21 has activity
on all leukocyte subsets, including dendritic cells and
Structure and mass spectrum of L4Figure 1
Structure and mass spectrum of L4.Page 3 of 6
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term survival of memory T cells [21].
The control peptide, with the mimetic sequence replaced
with VGGGSGGGS-, did not induce release of IL-8, IL-21
or other cytokines including IL-1β, IL-6, IL-10, IFN-γ and
TNF-α, (data not shown).
Conclusion
The multivalent peptide induced a remarkable pattern of
cytokine release. Secretions of several cytokines that are
used singly in clinical practice were stimulated, while
release of highly inflammatory cytokines, such as IL-1β,
IL-6 and TNF-α, did not appear to be changed.
Methods
Phage display library screening and DNA sequencing
The Ph.D.™-12 phage display library (New England
BioLabs, Ipswich, MA) was mixed with HPA conjugated to
agarose beads (Sigma-Aldrich, St. Louis, MO) at room
temperature in 200 μl of 50 mM Tris-HCl (pH 7.5) con-
taining 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2 and 1
mM MnCl2 (buffer A). The beads were washed three times
and suspended in 1 ml of buffer A. GalNAc was added to
the suspension to 100 mM and after 10 min the beads
were removed by centrifugation. Phage released from the
lectin were amplified by infection of E. coli strain ER2738
(New England BioLabs) and the screen was repeated three
times. The buffer for the last cycle included 0.5% (w/v)
Tween 20. Phage released by GalNAc were plated on a
lawn of E. coli and phage in individual plaques were
amplified and DNA was sequenced with an Applied Bio-
systems 3730 Analyzer (Applied Biosystems, Foster City,
CA) with the -96 gIII primer.
Synthesis of peptides
Quadravalent peptides were synthesized on a tri-Lys core
[13] utilizing Fmoc (9-fluorenylmethoxycarbonyl)-pro-
tected amino acids and a Milligen Biosearch 9050+ con-
tinuous flow peptide synthesizer (Millipore, Billerica,
MA). The C-terminus consisted of βAla(βA)-Cys(C). A
dansyl group was incorporated by reaction of the thiol
group on C-terminal Cys with 5-((((2-
iodoacetyl)amino)ethyl)amino)naphthalene-1-sulfonic
acid (IAEDANS) (Molecular Probes, Eugene, OR). Biotin
was incorporated into the peptide with C-terminal ε-bioti-
nyl-Lys in place of βAla-Cys. A control peptide was synthe-
sized with the sequence identified by phage display
replaced with a repeat of the spacer sequence (i.e.,
VGGGSGGGS-). Peptides were purified on a preparative
Jupiter Proteo C12 column (21.2 mm × 250 mm) (Phe-
nomenex, Torrance, CA) using a gradient from 8% to 18%
acetonitrile in water containing 0.1% TFA, dried under
vacuum, dissolved in sterile PBS, pH 7.2, and passed
through a Sephadex G-25 or G-15 column (1 × 45 cm) in
Binding of lectins to L4F gure 2
Binding of lectins to L4. (A) For each lectin, 4, 20 and 100 
ng were spotted in triplicate. One set of a total of four sets is 
shown in the figure. Spots in rows A-C, columns 1–3 con-
tained H. pomatia lectin (HPA), rows A-C, columns 4–6 con-
tained T. vulgare lectin (WGA), rows D-F, columns 1–3 
contained B. simplicifolia B4 (BS) and rows D-F, columns 4–6 
contained C. ensiformis lectin (ConA). The slide was incu-
bated with 2% gelatin to block non-specific sites. Biotin-
tagged peptide was incubated with the slide and then the 
amount of peptide bound was detected by binding of Cy3-
conjugated streptavidin and measuring fluorescence of the 
spots. In columns marked B, buffer A was spotted as blanks. 
(B) Biotin-tagged L4 or control peptide was bound in wells of 
a streptavidin-coated microtiter plate. The wells were 
blocked with 2% gelatin, washed, and then equal amounts (50 
ng) of lectins conjugated with peroxidase were added. After 
washing, the amount of lectin bound was detected by peroxi-
dase activity. Standard curves were determined with each 
lectin-peroxidase conjugate to quantitate binding. Data are 
expressed as the amount of lectin bound minus a blank with-
out peptide. Light blue bars, peptide L4; dark blue bars, con-
trol peptide.Page 4 of 6
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absorbance of the dansyl group (extinction coefficient,
εmM = 5.7 cm-1 at 336 nm) or by the bicinchoninic acid
assay (Pierce, Rockland, IL) using known concentrations
of the dansylated peptide as standard. Mass spectroscopy
was performed with a Voyager DE STR mass spectrometer
(Applied Biosystems).
Lectin binding
Horseradish peroxidase-conjugated lectins (Sigma-
Aldrich) were prepared at a concentration of 500 μg/ml in
buffer A and 1 μl of each was spotted 4 times in triplicate
onto a glass slide (Full Moon BioSystems, Sunnyvale, CA)
at dilutions of 1:5, 1:25 and 1:125. Buffer A was spotted
as blanks. The slide was blocked with 2% gelatin in buffer
A, and biotin-tagged L4 in buffer A was incubated with the
slide overnight at room temperature. The slide was
washed 3 times with buffer A and then incubated with
streptavidin conjugated with Cy3 (Sigma-Aldrich) for 1 h.
The slide was again washed 3 times with buffer A and flu-
orescence detected in a microarray reader.
For microtiter plate assays, 100 μl of 2 μM biotin-tagged
L4 in PBS was added to each well of a high-binding-capac-
ity streptavidin-coated plate (Pierce) and incubated over-
night at 4°C. The wells were blocked with 2% gelatin in
PBS for 3 h at room temperature, washed 1 time with PBS
and then with buffer A. Lectins were added at a concentra-
tion of 1 μg/ml in buffer A. After 1 h incubation, wells
were washed 4 times with buffer A containing 0.01%
Tween-20, 50 μl peroxidase substrate (1-Step Ultra TMB-
ELISA, Pierce) was then added, and after 5 min the reac-
tion was stopped with 50 μl 2 M H2SO4. Absorbance was
read immediately at 450 nm. Standard curves were
obtained by assaying known amounts of the horseradish
peroxidase-conjugated lectins (OD450/ng protein).
Cytokine assays
Human PBMCs (Cellular Technology Ltd, Shaker Heights,
OH) were plated at 4 × 105 cells per well in RPMI 1640
medium containing 10% fetal bovine serum (FBS). After
2 days at 37°C in 5% CO2, the medium was replaced and
peptide or LPS added and the incubation continued for 24
h. Media were then withdrawn and cytokines assayed with
BioSource kits (Invitrogen, Carlsbad, CA). For IL-21 anal-
yses, media were applied to Immobilon-P membranes
Quantitative analysis of cytokinesFigure 3
Quantitative analysis of cytokines. The amounts of sev-
eral cytokines in media of PBMC cultures treated for 24 h 
with L4 in the presence of 1 ng/ml LPS (+LPS) or in the 
absence (-LPS) were determined. (A) IL-1β, (B) IL-6, (C) IL-
10, (D) TNF-α, and (E) IL-8. The concentration of L4 in each 
assay is indicated. Assays were done in quadruplicate.
Stimulation of IL-21 release from PBMCs by treatment with L4Figure 4
Stimulation of IL-21 release from PBMCs by treat-
ment with L4. PBMCs were treated with 1 nM (400 U/ml) 
IFN-γ or 50 nM L4 for 16 h. The media were blotted onto 
membranes and stained with chicken anti-IL-21 antibodies 
and rabbit anti-chicken antibodies conjugated with peroxi-
dase. The graph shows mean ± SEM values of four measure-
ments.Page 5 of 6
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(Millipore) in a slot-blot apparatus, the membrane was
blocked with 5% nonfat dried milk in PBS, incubated
with a primary chicken polyclonal anti-IL-21 antibody
(Abcam, Cambridge, MA) and then with a rabbit polyclo-
nal anti-chicken IgY antibody (Abcam) conjugated with
horseradish peroxidase. Bound antibodies were detected
with 3,3',5,5'-tetramethylbenzidine substrate (Sigma-
Aldrich). Membranes were scanned with a densitometer
to quantitate the extent of reaction.
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Gal: galactose; GalNAc: N-acetylgalactosamine; G-CSF:
granulocyte colony-stimulating factor; Glc: glucose; Glc-
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